Literature DB >> 32964492

GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons.

Piotr Chmielarz1,2, Şafak Er1, Julia Konovalova1, Laura Bandres1, Irena Hlushchuk1, Katrina Albert1, Anne Panhelainen1, Kelvin Luk3, Mikko Airavaara1,4, Andrii Domanskyi1.   

Abstract

BACKGROUND: Parkinson's disease (PD) is associated with proteostasis disturbances and accumulation of misfolded α-synuclein (α-syn), a cytosolic protein present in high concentrations at pre-synaptic neuronal terminals. It is a primary constituent of intracellular protein aggregates known as Lewy neurites or Lewy bodies. Progression of Lewy pathology caused by the prion-like self-templating properties of misfolded α-syn is a characteristic feature in the brains of PD patients. Glial cell line-derived neurotrophic factor (GDNF) promotes survival of mature dopamine (DA) neurons in vitro and in vivo. However, the data on its effect on Lewy pathology is controversial.
OBJECTIVES: We studied the effects of GDNF on misfolded α-syn accumulation in DA neurons.
METHODS: Lewy pathology progression was modeled by the application of α-syn preformed fibrils in cultured DA neurons and in the adult mice.
RESULTS: We discovered that GDNF prevented accumulation of misfolded α-syn in DA neurons in culture and in vivo. These effects were abolished by deletion of receptor tyrosine kinase rearranged during transfection (RET) or by inhibitors of corresponding signaling pathway. Expression of constitutively active RET protected DA neurons from fibril-induced α-syn accumulation.
CONCLUSIONS: For the first time, we have shown the neurotrophic factor-mediated protection against the misfolded α-syn propagation in DA neurons, uncovered underlying receptors, and investigated the involved signaling pathways. These results demonstrate that activation of GDNF/RET signaling can be an effective therapeutic approach to prevent Lewy pathology spread at early stages of PD.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  GDNF; Parkinson's disease; alpha-synuclein; dopamine neuron; misfolded protein accumulation

Mesh:

Substances:

Year:  2020        PMID: 32964492     DOI: 10.1002/mds.28258

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease.

Authors:  Liliane Tenenbaum
Journal:  Mol Ther       Date:  2021-09-01       Impact factor: 12.910

2.  Cell Culture Media, Unlike the Presence of Insulin, Affect α-Synuclein Aggregation in Dopaminergic Neurons.

Authors:  Irena Hlushchuk; Justyna Barut; Mikko Airavaara; Kelvin Luk; Andrii Domanskyi; Piotr Chmielarz
Journal:  Biomolecules       Date:  2022-04-09

Review 3.  Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic.

Authors:  James A Conway; Edgar R Kramer
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

Review 4.  Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.

Authors:  Karen M Delgado-Minjares; Daniel Martinez-Fong; Irma A Martínez-Dávila; Cecilia Bañuelos; M E Gutierrez-Castillo; Víctor Manuel Blanco-Alvarez; Maria-Del-Carmen Cardenas-Aguayo; José Luna-Muñoz; Mar Pacheco-Herrero; Luis O Soto-Rojas
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 5.  Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.

Authors:  Päivi Lindholm; Mart Saarma
Journal:  Mol Psychiatry       Date:  2021-12-14       Impact factor: 13.437

Review 6.  Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration.

Authors:  Yulia A Sidorova; Mart Saarma
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

Review 7.  RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.

Authors:  Arun Kumar Mahato; Yulia A Sidorova
Journal:  Int J Mol Sci       Date:  2020-09-26       Impact factor: 5.923

Review 8.  Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases.

Authors:  Youngpyo Nam; Gyeong Joon Moon; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

Review 9.  Chemical and Biological Molecules Involved in Differentiation, Maturation, and Survival of Dopaminergic Neurons in Health and Parkinson's Disease: Physiological Aspects and Clinical Implications.

Authors:  Giulia Gaggi; Andrea Di Credico; Pascal Izzicupo; Giovanni Iannetti; Angela Di Baldassarre; Barbara Ghinassi
Journal:  Biomedicines       Date:  2021-06-29

Review 10.  An Update on Gene Therapy Approaches for Parkinson's Disease: Restoration of Dopaminergic Function.

Authors:  Amber D Van Laar; Victor S Van Laar; Waldy San Sebastian; Aristide Merola; J Bradley Elder; Russell R Lonser; Krystof S Bankiewicz
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.